Is pertuzumab a chemotherapy?

Pertuzumab is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug. This medication is classified as an “antineoplastic agent and a monoclonal antibody”. (For more detail, see “How Pertuzumab Works” below).

What is the main benefit of neoadjuvant therapy?

The advantages of neoadjuvant chemotherapy are 1) overall survival and recurrence-free survival rate are the same as post-operative chemotherapy, 2) serves as an in vivo sensitivity test, 3) increases the rate of breast conserving therapy, 4) facilitates the study of cancer biology.

What is the difference between Herceptin and PERJETA?

Perjeta targets a different area on the HER2 receptor than Herceptin does, so it’s believed to work in a way that is complementary to Herceptin. By blocking the signals, Perjeta can slow or stop the growth of the breast cancer. Perjeta and Herceptin are examples of immune targeted therapy.

What does Herceptin do to HER2?

These are known as HER2 positive cancers. About 1 in 5 breast and stomach cancers are HER2 positive. Herceptin works by blocking the effects of HER2 and encouraging the immune system (the body’s natural defences) to attack and kill the cancer cells.

Which is better neoadjuvant pertuzumab or trastuzumab?

The results from NeoSphere suggest that progression-free survival is improved when neoadjuvant pertuzumab is administered in combination with trastuzumab and docetaxel.

Is there a Phase 2 trial for pertuzumab?

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

Can you take Perjeta in combination with trastuzumab?

In the CLEOPATRA study, for patients with MBC, PERJETA in combination with trastuzumab and docetaxel was not associated with increases in the incidence of symptomatic left ventricular systolic dysfunction (LVSD) or decreases in LVEF compared to placebo in combination with trastuzumab and docetaxel.

Which is the best pertuzumab for breast cancer?

Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer Pertuzumab-based regimens, including THP, resulted in higher pCR rates as compared to ddAC-TH, with the THP regimen associated with the best tolerability among patients with localized HER2+ breast cancer.